Sirpa Jalkanen Selected Research

human AOC3 protein

2/2021	Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity.
11/2014	Endothelial amine oxidase AOC3 transiently contributes to adaptive immune responses in the airways.
6/2011	Identification of two imidazole binding sites and key residues for substrate specificity in human primary amine oxidase AOC3.
4/2004	Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sirpa Jalkanen Research Topics

Disease

51	Inflammation (Inflammations) 01/2022 - 01/2002
32	Neoplasms (Cancer) 11/2022 - 04/2003
6	Infections 12/2021 - 02/2004
6	Arthritis (Polyarthritis) 01/2021 - 09/2006
6	Atherosclerosis 01/2019 - 12/2002
5	Breast Neoplasms (Breast Cancer) 11/2022 - 10/2012
5	Hypoxia (Hypoxemia) 11/2021 - 12/2011
5	Neoplasm Metastasis (Metastasis) 10/2019 - 04/2003
4	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2006
4	Multiple Sclerosis 01/2021 - 09/2007
4	Carcinoma (Carcinomatosis) 12/2019 - 07/2009
4	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2019 - 02/2015
3	Vascular Remodeling 02/2022 - 05/2018
3	Pneumonia (Pneumonitis) 11/2021 - 03/2006
3	Obesity 02/2021 - 04/2004
3	Rheumatoid Arthritis 01/2021 - 11/2015
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 04/2014
3	Melanoma (Melanoma, Malignant) 10/2019 - 04/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 08/2014
3	Peripheral Arterial Disease 10/2018 - 03/2015
3	Fibrosis (Cirrhosis) 01/2017 - 02/2015
3	Experimental Melanoma 11/2016 - 01/2013
3	Insulin Resistance 01/2016 - 08/2006
3	Liver Diseases (Liver Disease) 02/2015 - 04/2004
2	Adenocarcinoma 09/2022 - 10/2010
2	Cytokine Release Syndrome 01/2022 - 11/2021
2	Bacterial Infections (Bacterial Infection) 12/2021 - 05/2010
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2019 - 08/2006
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2019 - 07/2008
2	Osteomyelitis 11/2019 - 08/2009
2	Retinal Perforations 01/2019 - 01/2017
2	Urinary Bladder Neoplasms (Bladder Cancer) 10/2017 - 01/2015
2	Peritonitis 11/2016 - 03/2005
2	Pancreatitis 01/2016 - 12/2014
2	Lymphoma (Lymphomas) 12/2014 - 08/2006
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2012 - 03/2005

Drug/Important Bio-Agent (IBA)

16	Peptides (Polypeptides)IBA 01/2022 - 08/2009
15	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2004
12	CytokinesIBA 11/2022 - 03/2008
12	Adenosine (Adenocard)FDA LinkGeneric 02/2022 - 02/2004
12	Adenosine Triphosphate (ATP)IBA 02/2022 - 05/2010
9	Biomarkers (Surrogate Marker)IBA 11/2022 - 08/2014
9	Oxidoreductases (Dehydrogenase)IBA 02/2021 - 09/2006
9	AminesIBA 02/2021 - 12/2002
9	EnzymesIBA 01/2019 - 12/2002
8	Adenosine Diphosphate (ADP)IBA 01/2019 - 05/2011
7	purineIBA 01/2020 - 05/2010
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2019 - 08/2009
6	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2021 - 11/2015
6	LectinsIBA 01/2021 - 11/2015
6	Sialic Acid Binding Immunoglobulin-like LectinsIBA 11/2019 - 01/2016
5	Immunoglobulin G (IgG)IBA 01/2022 - 05/2010
5	AntibodiesIBA 01/2021 - 03/2005
5	5'-Nucleotidase (5' Nucleotidase)IBA 01/2019 - 12/2014
5	Glycoproteins (Glycoprotein)IBA 01/2017 - 08/2009
4	Scavenger Receptors (Scavenger Receptor)IBA 12/2021 - 01/2016
4	human AOC3 proteinIBA 02/2021 - 04/2004
4	Pharmaceutical PreparationsIBA 01/2021 - 09/2007
4	LigandsIBA 01/2021 - 09/2011
4	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 11/2015
4	NucleotidesIBA 01/2017 - 12/2011
3	Interleukin-18 (Interleukin 18)IBA 11/2022 - 03/2008
3	Interleukin-6 (Interleukin 6)IBA 11/2021 - 03/2008
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 10/2010
3	NucleosidesIBA 01/2020 - 12/2014
3	IntegrinsIBA 10/2019 - 10/2012
3	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2019 - 09/2006
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 11/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2018 - 01/2013
3	Mannose ReceptorIBA 01/2018 - 08/2003
3	Collagen Type II (Type II Collagen)IBA 01/2018 - 09/2006
3	Phenobarbital (Luminal)FDA Link 11/2015 - 06/2005
3	Glucose (Dextrose)FDA LinkGeneric 02/2012 - 08/2006
3	Insulin (Novolin)FDA Link 08/2006 - 12/2002
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 11/2022 - 03/2008
2	Interferon-gamma (Interferon, gamma)IBA 11/2022 - 10/2013
2	AntigensIBA 09/2022 - 08/2006
2	Retinaldehyde (Retinal)IBA 02/2022 - 01/2019
2	bexmarilimabIBA 01/2022 - 01/2021
2	Folic Acid (Vitamin M)FDA LinkGeneric 01/2021 - 12/2019
2	LipidsIBA 01/2021 - 12/2019
2	C-Reactive ProteinIBA 11/2020 - 03/2008
2	CD39 antigenIBA 01/2019 - 03/2015
2	Adenylate KinaseIBA 01/2019 - 01/2017
2	CholesterolIBA 01/2019 - 08/2014
2	Adenosine DeaminaseIBA 01/2019 - 12/2014
2	Interleukin-17 (Interleukin 17)IBA 01/2019 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2018 - 11/2016
2	TurpentineIBA 01/2018 - 10/2010
2	MannansIBA 01/2018 - 01/2018
2	Monoclonal AntibodiesIBA 01/2018 - 06/2005
2	PurinesIBA 02/2015 - 12/2014
2	Purinergic P1 Receptors (Adenosine Receptor)IBA 12/2014 - 12/2014
2	Amine Oxidase (Copper-Containing)IBA 11/2014 - 03/2006
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 10/2012 - 03/2008
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 10/2012 - 03/2008
2	Messenger RNA (mRNA)IBA 05/2011 - 07/2010

Therapy/Procedure

10	Therapeutics 01/2021 - 03/2005
4	Immunotherapy 01/2021 - 10/2009
2	Cystectomy 10/2017 - 01/2015